Celera Corporation
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
35
Ending by 2030
May 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Genetic polymorphisms, associated with rheumatoid arthritis, methods of detection and uses thereof (US 10,301,679) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 3 fees due Jan 2 to 11, 2027 · next Jan 2
- 3 fees due Apr 8 to 30, 2027 · next Apr 8
- 2 fees due May 14 to 28, 2027 · next May 14
- 2 fees due Aug 4 to 18, 2027 · next Aug 4
- 1 fee due Sep 10, 2027The maintenance fee for Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof (US 10,584,384) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,486,392 | Methods and compositions for diagnosing and treating diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 8,975,022 | Genetic Polymorphisms Associated with Psoriasis, Methdos of Detection and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,371,565 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,006,088 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,920,276 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,988,809 | Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,814,684 | Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,550,433 | Polymorphism in the Apo(A) Gene Predict Responsiveness to Acetylsalicylic Acid Treatment In force · High confidence | In force | High confidence | |
| US 11,028,445 | Molecular prognostic signature for predicting breast cancer metastasis, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 7,727,725 | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 47: 7 patents in force now held by others · 250 lapsed for an unpaid fee · 14 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 31 abandoned · 73 no status recorded